<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">8110075</journal-id><journal-id journal-id-type="pubmed-jr-id">423</journal-id><journal-id journal-id-type="nlm-ta">Am J Kidney Dis</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Kidney Dis.</journal-id><journal-title-group><journal-title>American journal of kidney diseases : the official journal of the National Kidney Foundation</journal-title></journal-title-group><issn pub-type="ppub">0272-6386</issn><issn pub-type="epub">1523-6838</issn></journal-meta><article-meta><article-id pub-id-type="pmid">32305206</article-id><article-id pub-id-type="pmc">7387135</article-id><article-id pub-id-type="doi">10.1053/j.ajkd.2020.01.007</article-id><article-id pub-id-type="manuscript">NIHMS1568543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>CKD Awareness Among US Adults by Future Risk of Kidney
Failure</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chu</surname><given-names>Chi D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>McCulloch</surname><given-names>Charles E.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Banerjee</surname><given-names>Tanushree</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pavkov</surname><given-names>Meda E.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Burrows</surname><given-names>Nilka R.</given-names></name><degrees>MPH</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Gillespie</surname><given-names>Brenda W.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Saran</surname><given-names>Rajiv</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shlipak</surname><given-names>Michael G.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Powe</surname><given-names>Neil R.</given-names></name><degrees>MD, MPH, MBA</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A7">7</xref></contrib><contrib contrib-type="author"><name><surname>Tuot</surname><given-names>Delphine S.</given-names></name><degrees>MDCM, MAS</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A7">7</xref></contrib><on-behalf-of>Centers for Disease Control and Prevention Chronic Kidney Disease
Surveillance Team</on-behalf-of></contrib-group><aff id="A1"><label>1</label>Department of Medicine, University of California San
Francisco, San Francisco, CA</aff><aff id="A2"><label>2</label>Department of Biostatistics and Epidemiology, University of
California San Francisco, San Francisco, CA</aff><aff id="A3"><label>3</label>Division of Diabetes Translation, Centers for Disease
Control and Prevention, Atlanta, GA</aff><aff id="A4"><label>4</label>Kidney Epidemiology and Cost Center, University of
Michigan, Ann Arbor, Michigan</aff><aff id="A5"><label>5</label>Division of Nephrology, Department of Medicine, University
of Michigan, Ann Arbor, Michigan</aff><aff id="A6"><label>6</label>Kidney Health Research Collaborative, San Francisco
Veterans Affairs Hospital, San Francisco, California</aff><aff id="A7"><label>7</label>Department of Medicine, Priscilla Chan and Mark Zuckerberg
San Francisco General Hospital, San Francisco, California</aff><author-notes><fn fn-type="other" id="FN1"><p id="P1">CDC CKD Surveillance Team: University of Michigan: Rajiv Saran (PI),
Vahakn Shahinian, Michael Heung, Brenda Gillespie, Hal Morgenstern, William
Herman, Kara Zivin, Jennifer Bragg-Gresham, Diane Steffick, Yun Han,
Xiaosong Zhang, Yiting Li, Vivian Kurtz, April Wyncott; University of
California, San Francisco: Neil Powe (PI), Tanushree Banerjee, Delphine
Tuot, Chi-yuan Hsu, Charles McCulloch, Deidra Crews, Raymond Hsu, Kirsten
Johansen, Michael Shlipak, Janet Canela; Centers for Disease Control and
Prevention: Nilka R&#x000ed;os Burrows (Technical Advisor), Mark Eberhardt,
Juanita Mondesire, Priti Patel, Meda Pavkov, Deborah Rolka, Sharon Saydah,
Sundar Shrestha, Larry Waller.</p></fn><fn fn-type="con" id="FN2"><p id="P2">Authors&#x02019; Contributions:</p><p id="P3">research idea and study design: CDC, TB, MEP, NRB, BWG, RS, MGS, DST,
NRP; data acquisition: CDC; data analysis/interpretation: CDC, CEM, DST;
statistical analysis: CDC, CEM, DST; supervision or mentorship: DST, NRP.
Each author contributed important intellectual content during manuscript
drafting or revision, accepts personal accountability for the
author&#x02019;s own contributions, and agrees to ensure that questions
pertaining to the accuracy or integrity of any portion of the work are
appropriately investigated and resolved.</p></fn><corresp id="CR1"><bold>Corresponding Author</bold>: Chi D. Chu, MD, University of
California, San Francisco, Division of Nephrology, Department of Medicine, 533
Parnassus Avenue, U404, San Francisco, CA 94143-0532, Telephone: (415) 476-1812,
<email>Chi.Chu@ucsf.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>2</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>8</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>8</month><year>2021</year></pub-date><volume>76</volume><issue>2</issue><fpage>174</fpage><lpage>183</lpage><!--elocation-id from pubmed: 10.1053/j.ajkd.2020.01.007--><abstract id="ABS1"><sec id="S1"><title>Rationale &#x00026; Objective:</title><p id="P4">Persons with chronic kidney disease (CKD) are often unaware of their
disease status. Efforts to improve CKD awareness may be most impactful if
focused on persons at highest risk of progression to kidney failure.</p></sec><sec id="S2"><title>Study Design:</title><p id="P5">Serial cross-sectional surveys.</p></sec><sec id="S3"><title>Setting &#x00026; Participants:</title><p id="P6">Non-pregnant adults (age &#x02265;20 years) with CKD glomerular
filtration rate categories 3&#x02013;4 (G3-G4) who participated in the
National Health and Nutrition Examination Survey from 1999&#x02013;2016
(n=3,713).</p></sec><sec id="S4"><title>Predictor:</title><p id="P7">5-year kidney failure risk, estimated by the Kidney Failure Risk
Equation (KFRE). Predicted risk was categorized as minimal (&#x0003c;2%), low
(2%-&#x0003c;5%), intermediate (5%-&#x0003c;15%), or high (&#x02265;15%).</p></sec><sec id="S5"><title>Outcome:</title><p id="P8">CKD awareness, defined by answering &#x0201c;yes&#x0201d; to the
question, &#x0201c;Have you ever been told by a doctor or other health
professional that you had weak or failing kidneys?&#x0201d;.</p></sec><sec id="S6"><title>Analytical Approach:</title><p id="P9">Prevalence of CKD awareness was estimated within each risk group
using complex sample survey methods. Associations between KFRE risk and CKD
awareness were assessed using multivariable logistic regression. CKD
awareness was compared with awareness of hypertension and diabetes over the
same time period.</p></sec><sec id="S7"><title>Results:</title><p id="P10">In 2011&#x02013;2016, unadjusted CKD awareness was 9.6%, 22.6%,
44.7%, and 49.0% in the minimal, low, intermediate, and high risk groups
respectively. In adjusted analyses, these proportions did not change over
time. Awareness of CKD, including among the highest risk group, remains
consistently below that of hypertension and diabetes and awareness of these
conditions did increase over time.</p></sec><sec id="S8"><title>Limitations:</title><p id="P11">Imperfect sensitivity of the &#x0201c;weak or failing kidneys&#x0201d;
question for ascertaining CKD awareness.</p></sec><sec id="S9"><title>Conclusions:</title><p id="P12">Among adults with CKD G3-G4 who have 5-year estimated risks of
kidney failure of 5%- &#x0003c;15% and &#x02265;15%, approximately half were
unaware of their kidney disease, a gap that has persisted nearly two
decades.</p></sec></abstract><kwd-group><kwd>chronic kidney disease (CKD)</kwd><kwd>CKD awareness</kwd><kwd>public health</kwd><kwd>estimated glomerular filtration rate (eGFR)</kwd><kwd>urinary albumin-creatinine ratio (UACR)</kwd><kwd>albuminuria</kwd><kwd>renal function</kwd><kwd>renal insufficiency</kwd><kwd>kidney failure prevention</kwd><kwd>disease management</kwd><kwd>patient empowerment</kwd><kwd>self care</kwd><kwd>health literacy</kwd><kwd>nationally representative survey</kwd></kwd-group></article-meta></front><body><sec id="S10"><title>Introduction</title><p id="P13">Chronic kidney disease (CKD) affects approximately 15% of the U.S. adult
population, and nine out of ten adults with the disease are not aware of having
it.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> While there is some suggestion that patient
awareness of CKD may have increased among persons with CKD stage 4 from 2009 to
2016<sup><xref rid="R1" ref-type="bibr">1</xref></sup>, numerous studies
have found low overall CKD awareness across racially/ethnically and geographically
diverse populations.<sup><xref rid="R3" ref-type="bibr">3</xref>&#x02013;<xref rid="R8" ref-type="bibr">8</xref></sup> It is generally assumed that
awareness of disease is an important stimulus for early preventive care, including
minimizing nephrotoxic medications and guiding treatments to slow kidney disease
progression.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> To date, studies examining this assumption
have failed to show robust associations between CKD awareness and blood pressure
control, glycemic control, non-steroidal anti-inflammatory drug (NSAID) avoidance,
and general CKD self-management knowledge and behaviors.<sup><xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R15" ref-type="bibr">15</xref></sup></p><p id="P14">While these data may temper enthusiasm surrounding diagnostic disclosure of
CKD, patient awareness remains an important component of CKD management and
preventive care. One argument is that all patients should be aware of all their
diagnoses, no matter how consequential, unless they specifically indicate
otherwise&#x02014;and that withholding the diagnosis could represent a paternalistic
practice.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> In addition,
knowledge of CKD diagnosis can reinforce adherence to lifestyle changes and
treatments for shared cardiovascular and kidney-related risk factors; patient
counseling may be framed in the context of decreasing the risk of worsening kidney
function and forestalling or preventing the need for dialysis.</p><p id="P15">Controversy surrounding the value of CKD awareness is largely due to the
uncertainty of whether CKD progression from early to late stages would be prevented
if CKD awareness were greater. While it would be ideal for all persons with CKD to
be aware of their condition, CKD awareness is almost certainly most relevant to
those at greatest risk for CKD-specific complications, including need for kidney
replacement therapy (KRT). The objectives of this study were to estimate CKD
awareness in a nationally representative population sample according to risk of
progression to kidney failure, and to determine whether awareness has changed over
time among those with highest risk of progression to kidney failure.</p></sec><sec id="S11"><title>Methods</title><sec id="S12"><title>Study Design</title><p id="P16">The National Health and Nutrition Examination Survey (NHANES) is a
nationally representative cross-sectional survey of noninstitutionalized U.S.
civilian residents that has been conducted continuously since 1999 by the
Centers for Disease Control and Prevention&#x02019;s National Center for Health
Statistics. The survey obtains cross-sectional prevalence estimates and, when
combined over multiple years, can identify national trends in disease
prevalence. NHANES consists of an interview component, a physical examination
component, and a laboratory testing component. The NHANES protocol was approved
by the National Center for Health Statistics Research Ethics Review Board
(protocol #98&#x02013;12, #2005&#x02013;06, #2011&#x02013;17), and informed consent
was obtained from all study participants. We examined data from NHANES from 1999
to 2016.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p></sec><sec id="S13"><title>Study Population</title><p id="P17">Of the 92,062 NHANES participants 1999 to 2016, our study population
included survey participants age 20 years or older and who were not pregnant
(remaining n = 48,026). For analyses of CKD awareness, we excluded participants
with missing data on age, sex, race, serum creatinine, or urinary
albumin-creatinine ratio (UACR), as this information is required for calculation
of estimated glomerular filtration rate (eGFR) and estimation of kidney failure
risk (remaining n = 42,106). We excluded participants who did not have CKD GFR
categories 3 or 4 (G3-G4), as defined by eGFR &#x02265;15 and &#x0003c;60
mL/min/1.73m<sup>2</sup> (remaining n = 3,728). Participants with eGFR
&#x0003c;15 mL/min/1.73m<sup>2</sup> were excluded due to low sample size (n =
97) and an inability to differentiate reliably those on dialysis from those with
advanced but non-KRT-requiring CKD. Finally, we excluded participants who did
not answer &#x0201c;Yes&#x0201d; or &#x0201c;No&#x0201d; to the question on
awareness of CKD (final n for CKD awareness analysis = 3,713).</p></sec><sec id="S14"><title>Definitions</title><p id="P18">CKD G3-G4 was defined by eGFR &#x02265;15 and &#x0003c;60
ml/min/1.73m<sup>2</sup>, as calculated using the CKD-EPI
equation.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> The 5-year
risk of kidney failure was estimated using the 4-variable Kidney Failure Risk
Equation (KFRE), which uses age, sex, eGFR, and UACR to predict risk of kidney
failure over time (<xref rid="SD1" ref-type="supplementary-material">Item
S1</xref>).<sup><xref rid="R19" ref-type="bibr">19</xref></sup> The KFRE is
a publicly available risk prediction model initially developed and validated in
a retrospective cohort of Canadian CKD patients; it has demonstrated excellent
discriminatory performance in subsequent validation studies using diverse
multinational cohorts.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> We categorized KFRE-predicted
risk into four levels: minimal risk (&#x0003c;2%), low risk (2 to &#x0003c;5%),
moderate risk (5 to &#x0003c;15%), and high risk (15% or greater). These cutoffs
were selected to represent clinically meaningful risk delineations suggested by
prior studies.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup></p><p id="P19">CKD awareness was defined among those with CKD as a &#x0201c;yes&#x0201d;
answer to the interview question &#x0201c;Have you ever been told that you have
weak or failing kidneys? Do not include kidney stones, bladder infections, or
incontinence.&#x0201d;</p><p id="P20">For comorbidities, hypertension was defined as either systolic blood
pressure &#x02265;140 mmHg, diastolic blood pressure &#x02265;90 mmHg, or current
use of antihypertensive medication.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> If more than one blood pressure reading was measured,
the mean systolic value and mean diastolic value across all readings were used.
Diabetes was defined by hemoglobin A1c &#x02265;6.5% or current use of diabetes
medication.<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p></sec><sec id="S15"><title>Statistical Methods</title><p id="P21">Combining all survey years 1999&#x02013;2016, the proportion of persons
aware of CKD was estimated within each risk group. To assess for temporal
trends, we examined CKD awareness during three consecutive six-year intervals:
1999&#x02013;2004, 2005&#x02013;2010, and 2011&#x02013;2016. Multiple survey years
were aggregated to ensure sufficient cell sizes for analysis within each time
interval and KFRE risk group. The unadjusted prevalence of CKD awareness was
estimated during each time interval, by KFRE risk group. Temporal trends in CKD
awareness were assessed by fitting logistic regression models using time
interval as a categorical predictor, then using contrasts to test for linear
trends in the corresponding coefficients.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p id="P22">The association between KFRE risk and CKD awareness was examined using
multivariable logistic regression, adjusting for demographic variables and
comorbidities previously associated with CKD awareness. Because the question of
whether CKD definition should use an age-adapted eGFR is an issue of current
interest,<sup><xref rid="R27" ref-type="bibr">27</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref></sup> we also examined whether the
association between KFRE risk and CKD awareness varied by age. For this
analysis, age was categorized as 20&#x02013;64, 65&#x02013;74, and &#x02265;75
years. Using logistic regression with an interaction term for age and KFRE risk,
marginal predictions of CKD awareness were obtained for each KFRE risk group
according to age category.</p><p id="P23">As a secondary analysis, we compared awareness of CKD to awareness of
other common chronic conditions, namely, hypertension and diabetes. For this
analysis, hypertension awareness was defined as either self-reported
hypertension (defined by answering &#x0201c;yes&#x0201d; to the question
&#x0201c;Have you ever been told by a doctor or other health professional that
you had hypertension, also called high blood pressure?&#x0201d;) or self-reported
use of prescription medication for high blood pressure, among persons with
hypertension. Diabetes awareness was defined as either self-reported diabetes
(defined by answering &#x0201c;yes&#x0201d; to the question &#x0201c;Other than
during pregnancy, have you ever been told by a doctor or health professional
that you have diabetes or sugar diabetes?&#x0201d;) or self-reported insulin or
diabetic pill use, among persons with diabetes.</p><p id="P24">Analyses were performed using Stata/IC version 15.1 (StataCorp, College
Station, Texas, USA). Adjustments were made to account for historical laboratory
creatinine calibration issues according to NHANES analytical guidelines (<xref rid="SD1" ref-type="supplementary-material">Item S2</xref>). All estimates
in NHANES were weighted to the U.S. population using the appropriate sample
weights with variance computed accounting for strata and primary sampling units.
All reported estimates were based on &#x0003e;8 degrees of freedom, and all had
relative standard error &#x0003c;30%, in accordance with NHANES analytic
guidelines and the National Center for Health Statistics Data Presentation
Standards for Proportions.<sup><xref rid="R30" ref-type="bibr">30</xref></sup></p></sec></sec><sec id="S16"><title>Results</title><sec id="S17"><title>Participant Characteristics</title><p id="P25">Baseline characteristics of NHANES participants with CKD G3-G4 (n =
3,713) are described in <xref rid="T1" ref-type="table">Table 1</xref>. Higher
KFRE risk was more common among men, persons of non-white race/ethnicity,
persons with diabetes, and persons with hypertension. The mean eGFR ranged from
52 mL/min/1.73m<sup>2</sup> in the minimal KFRE risk group to 26
mL/min/1.73m<sup>2</sup> in the highest risk group; median UACR ranged from
9 mg/g to 934 mg/g across these groups of KFRE risk. The proportion of persons
with any type of health insurance was high at approximately 96% and was similar
across all risk groups, although in higher risk groups, Medicaid was more common
(14.4% in the highest risk group versus 6.6% in the lowest) and private
insurance was less common (48.9% versus 61.2%, respectively).</p></sec><sec id="S18"><title>Proportion Aware of CKD</title><p id="P26">Among adults with CKD G3-G4 and &#x0003c;2% KFRE risk, 7.0% (95% CI,
5.9%&#x02212;8.3%) were aware of their CKD; among those with 2%-&#x0003c;5% KFRE
risk, 18.7% (95% CI, 14.0%&#x02212;23.4%) were aware; among those with
5%-&#x0003c;15% KFRE risk, 43.4% (95% CI, 36.4%&#x02212;50.5%) were aware; and
among those with &#x02265;15% KFRE risk, 49.6% (95% CI, 41.1%&#x02212;58.2%) were
aware.</p><p id="P27">Consistently over time, crude prevalence of CKD awareness was higher
with higher KFRE risk group (<xref rid="F1" ref-type="fig">Figure 1</xref>,
panel A). In analyses of awareness over time, unadjusted analyses showed a
borderline statistically significant trend only among those at minimal KFRE risk
(6.3% [95% CI, 4.3%&#x02212;8.3%] in 1999&#x02013;2004 and 9.6% [95% CI,
7.4%&#x02212;11.8% in 2011&#x02013;2016]; p<sub>trend</sub> = 0.03). In other KFRE
risk groups, no statistically significant trends were found: CKD
awareness estimates in the 2%-&#x0003c;5% KFRE risk group were numerically higher
in 2011&#x02013;2016 (22.6%; 95% CI, 14.7%&#x02212;30.4%) than in 1999&#x02013;2004
(14.6%; 95% CI, 6.6%&#x02212;22.5%) but this was not statistically significant
(p<sub>trend</sub> = 0.2); awareness in higher risk groups ranged from 42%
to 50% (p<sub>trend</sub> = 0.8 and 0.9, respectively).</p><p id="P28">Similar results were obtained when analyses were conducted for direct
age-standardized CKD awareness (<xref rid="F1" ref-type="fig">Figure 1</xref>,
panel B), and then with adjustment for sex, age, race/ethnicity, presence of
hypertension, and presence of diabetes (<xref rid="F1" ref-type="fig">Figure
1</xref>, panel C). No statistically significant trends were observed in any
KFRE risk groups in either age-standardized or adjusted analyses.</p></sec><sec id="S19"><title>Association of Kidney Failure Risk with CKD Awareness</title><p id="P29">The association between KFRE risk and CKD awareness was examined using
multivariable logistic regression (<xref rid="T2" ref-type="table">Table
2</xref>). In both unadjusted and adjusted models, the odds of CKD awareness
were greater with each category of higher KFRE risk. Odds of CKD awareness were
similar in the two highest risk groups (5%-&#x0003c;15% and &#x02265;15%).
Associations between CKD awareness and each KFRE risk group were all
statistically significant (p &#x0003c;0.01 for each).</p><p id="P30"><xref rid="F2" ref-type="fig">Figure 2</xref> shows unadjusted and
adjusted CKD awareness by KFRE risk and age categories. Findings were overall
similar between unadjusted and adjusted analyses. CKD awareness was greater with
increasing kidney failure risk, except among the highest risk group in the
20&#x02013;64 age category. The &#x02265;75 age category consistently had the
lowest awareness across the all risk groups. Of note, interpretation of these
interactions is limited due to wide confidence intervals, and p values for
interaction were nonsignificant in both unadjusted and adjusted analyses.</p></sec><sec id="S20"><title>Comparison of Awareness of CKD, Hypertension, and Diabetes</title><p id="P31"><xref rid="F3" ref-type="fig">Figure 3</xref> shows trends in awareness
of diabetes and hypertension over the study time period, compared to CKD (all
CKD G3-G4) and high-risk CKD (CKD with &#x02265;15% risk of kidney failure at 5
years as determined by the KFRE). From 1999&#x02013;2016, hypertension and
diabetes awareness were both consistently higher than CKD awareness in all CKD
G3-G4 and in high-risk CKD. During this period, both hypertension and diabetes
exhibited an increase in prevalence of disease awareness (p<sub>trend</sub> &#x0003c; 0.001
for both).</p></sec></sec><sec id="S21"><title>Discussion</title><p id="P33">In this nationally representative sample of U.S. adults, we found that while
CKD awareness was higher among persons with higher 5-year kidney failure risk,
approximately half of the participants with &#x02265;15% risk of developing kidney
failure within 5 years were unaware of having kidney disease. Additionally, no
statistically significant trends over time were observed in CKD awareness for any
risk groups except among those with minimal risk CKD, but this trend was not
significant in adjusted analyses. After adjustment for demographic factors and
comorbidities, we found that higher predicted kidney failure risk was associated
with increased odds of CKD awareness.</p><p id="P34">Our findings that CKD awareness is markedly lower for persons with CKD, even
those at the highest levels of risk for kidney failure, compared to all persons with
hypertension or diabetes regardless of their future risk for adverse events
underscores the need for the Public Awareness Initiative for Advancing American
Kidney Health launched by the National Kidney Foundation, American Society of
Nephrology, and the U.S. Department of Health and Human Services.<sup><xref rid="R41" ref-type="bibr">30a</xref></sup> This initiative aims to elevate
kidney disease awareness and includes an accompanying Kidney Risk Campaign.
Additionally, both diabetes and hypertension awareness demonstrate an increase over
time with statistically significant ptrend values. The trend in awareness for CKD
G3-G4 was not significant in adjusted analyses; furthermore, no statistically
significant trends were observed in the high-risk CKD group&#x02014;a group for whom
the practical implications of CKD are potentially most clinically relevant.</p><p id="P35">There are several possible factors contributing to low CKD awareness. In one
study of audio-taped primary care encounters, CKD was less commonly discussed
compared to hypertension or diabetes, and most CKD discussions were limited to
technical discussion of laboratory results, rather than on risk factors, prevention,
or complications.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Other possible
contributing factors may be provider under-recognition, lack of CKD knowledge or
familiarity on the part of primary care providers, and fear of overwhelming
patients, as compared to hypertension or diabetes.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></p><p id="P36">A somewhat surprising finding was the similarity in CKD awareness between
the intermediate risk (5%-&#x0003c;15% KFRE risk at 5 years) and the high risk
(&#x02265;15%) groups. Both categories of risk were associated with approximately 9
times odds of awareness compared to the minimal risk group. The decision not to
disclose CKD to patients has been, at least in part, attributed to the view that
there is little benefit to CKD disclosure when kidney disease is mild, has no
immediate treatment implications, and is likely to cause undue anxiety in patients
who are worried they will need dialysis or kidney transplantation.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> If clinicians&#x02019; efforts to
notify and educate patients about CKD are related to kidney disease severity, then
similar rates of awareness between intermediate and high levels of risk would
suggest that clinicians are failing to discriminate between these levels of risk in
patients with CKD. While persons in the highest risk group had a mean eGFR that was
7 ml/min/1.73m<sup>2</sup> lower than those in the intermediate risk group (33
versus 26 ml/min/1.73m<sup>2</sup>), they had substantially more albuminuria (median
UACRs of 934 vs 63 mg/g). Prior studies have shown proteinuria to be an uncommon
reason for nephrology referral, suggesting that a possible reason why clinicians
fail to recognize high risk kidney disease may be a relative underappreciation of
the prognostic significance of albuminuria compared to eGFR for predicting renal and
cardiovascular outcomes.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> Risk assessment using KFRE would reinforce
the importance of albuminuria measurement and allow clinicians to assess risk more
effectively and objectively for patients with CKD. KFRE utilization in primary care
could help risk stratify patients with CKD and inform appropriate counseling, as
well as next steps in workup and referral.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup></p><p id="P37">We found no statistically significant effect modification of age on the
association between KFRE risk and CKD awareness. Except in the highest KFRE risk
group, CKD awareness was higher in younger age groups. Of the multiple
provider-level factors (recognition, disclosure) and patient-level factors (e.g.,
health literacy, denial) that may affect awareness, the observed findings are
suggestive of several possibilities.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> One possible provider-level factor would be a higher threshold
for disclosure for mild CKD at older age. This may be due to a view that kidney
disease is a part of normal aging, and that labeling or disclosure may lead to undue
anxiety and stigma for otherwise well patients.<sup><xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R37" ref-type="bibr">37</xref></sup> This behavior, whether intentional or not,
is much in keeping with the recent conversation surrounding whether the eGFR-based
definition of CKD should be age-adapted, based on physiologic age-related kidney
function decline as well as examination of age-dependent differences in mortality
risk associated with eGFR.<sup><xref rid="R27" ref-type="bibr">27</xref>&#x02013;<xref rid="R29" ref-type="bibr">29</xref></sup> In
particular, it has been suggested that the threshold eGFR for CKD definition should
be higher with younger age (75 ml/min/1.73m<sup>2</sup> for age &#x0003c;45) and
lower with older age (45 ml/min/1.73m<sup>2</sup> for age &#x0003e;65). Another
possibility is if providers are under-recognizing CKD in older age groups, which is
plausible if older individuals are more likely to have creatinine tested for reasons
other than kidney health, thereby leading to incidental detection of CKD. Additional
study would be needed to discern the extent to which age-related differences in
provider recognition versus disclosure (versus patient-level factors) lead to
different rates of CKD awareness. However, these findings should be interpreted with
caution given the uncertainty associated with awareness estimates due to small
sample sizes in higher KFRE risk groups.</p><p id="P38">This study benefits from capturing a nationally representative population
over an extended time period spanning 18 years. It also represents a use of the KFRE
as a method to stratify our analysis based on each person&#x02019;s risk for a
meaningful clinical outcome, rather than stratifying by disease definitions such as
CKD stage or albuminuria, which are not as directly patient-centered. Our study
examined the CKD population through a lens of predicted risk rather than observed
outcomes, providing a more coherent and actionable framework for guiding CKD
awareness efforts and focusing on persons at high risk of kidney failure. By
directly showing low awareness among persons with high predicted kidney failure
risk, we define a discrete population&#x02014;identifiable based on presently
obtainable laboratory and demographic information&#x02014;in which awareness efforts
may be intensified. As the basis for risk-based care, this helps further underscore
the importance of albuminuria testing for risk stratification to guide referral,
counseling, and treatment decisions.</p><p id="P39">The primary limitation of this study was the imperfect sensitivity of the
question used in NHANES for ascertaining awareness of kidney disease. Ascertainment
of CKD awareness among persons with laboratory-defined CKD can differ according to
how the question is asked, with the NHANES question referring to &#x0201c;weak or
failing kidneys&#x0201d; being relatively less sensitive compared to different
phrases to describe CKD.<sup><xref rid="R38" ref-type="bibr">38</xref>,<xref rid="R39" ref-type="bibr">39</xref></sup> Clinicians may describe CKD to
patients in a variety of ways (e.g., weak kidneys, kidney disease, poor kidney
function, protein in the urine), and the best question to ascertain CKD awareness
has not been conclusively established; a study has shown that a compound question or
combining multiple questions may increase the yield.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> However, the present question remains the
most readily available way to obtain consistent, nationally representative estimates
of trends in CKD awareness. Given that improving awareness of kidney disease has
been announced in 2019 as a priority of the Advancing American Kidney Health
initiative, better validated tools are needed for improved measurement and national
surveillance of CKD awareness.</p><p id="P40">Additional limitations included small numbers of persons with advanced CKD,
which precluded more precise estimation and analysis of CKD awareness in higher risk
groups. Because of the cross-sectional nature of NHANES, the diagnosis of CKD was
based on a single measurement of creatinine and albuminuria, whereas the gold
standard definition requires two abnormal laboratory parameters separated by at
least three months.<sup><xref rid="R40" ref-type="bibr">40</xref></sup> Similarly,
hypertension and diabetes diagnoses may be subject to misclassification due to
definitions based on a single timepoint. Finally, the cross-sectional design does
not allow any inference with respect to whether or how kidney failure risk might
lead to CKD awareness.</p><p id="P41">In summary, we found in a nationally representative sample that
approximately half of persons with CKD and high risk of progression to kidney
failure (&#x02265;15% within 5 years) were unaware of having kidney disease, and
among those with minimal (&#x0003c;2%) risk, less than 10% were aware. The
heterogeneity of kidney failure risk also likely contributes to difficulty in
demonstrating the effects of CKD awareness in the overall CKD population. Future
studies of CKD awareness should present risk-stratified results, as this may better
direct public health efforts. While there may be some debate about the disclosure of
CKD diagnosis for those with milder degrees of CKD and low risk of progression, the
finding that such a large proportion of persons with the highest risk of needing
dialysis or kidney transplantation within 5 years are unaware of having kidney
disease is highly concerning, particularly as awareness in this group remains below
that of hypertension and diabetes, and has not changed with time. Despite broadly
directed efforts by many organizations to raise overall awareness of kidney disease
over the years, CKD awareness has remained largely unchanged for 18 years. The 2019
executive order on Advancing American Kidney Health initiative was an unprecedented
step in garnering nationwide attention surrounding kidney disease, bringing it
directly into the national spotlight. The subsequent announcement of the Public
Awareness Initiative, which is to include a nationwide Kidney Risk Campaign, is an
exciting and welcome step we should all look forward to with great anticipation.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><caption><p id="P45">Item S1. Calculation of 5-year kidney failure risk.</p><p id="P46">Item S2. Analytical issues.</p></caption><media xlink:href="NIHMS1568543-supplement-1.pdf" orientation="portrait" id="d39e606" position="anchor"/></supplementary-material></sec></body><back><ack id="S22"><title>Support:</title><p id="P42">This investigation was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases of the National Institutes of Health under the Ruth L.
Kirschstein National Research Service Award 1F32DK122629-01, and by the Supporting,
Maintaining and Improving the Surveillance System for Chronic Kidney Disease in the
U.S., Cooperative Agreement Number, U58 DP006254, funded by the Centers for Disease
Control and Prevention. The funders of this study had no role in study design;
collection, analysis, and interpretation of data; writing the report; and the
decision to submit the report for publication.</p></ack><fn-group><fn id="FN4"><p id="P43" content-type="publisher-disclaimer">This is a PDF file of an unedited
manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will
undergo copyediting, typesetting, and review of the resulting proof before it is
published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.</p></fn><fn fn-type="COI-statement" id="FN6"><p id="P49">Financial Disclosure: The authors declare that they have no relevant
financial interests.</p></fn><fn id="FN7"><p id="P50" content-type="publisher-disclaimer">Disclaimer: The findings and
conclusions in this report are solely those of the authors and do not
necessarily represent the official position of the Centers for Disease Control
and Prevention or the Department of Health and Human Services.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Saran</surname><given-names>R</given-names></name>, <name><surname>Robinson</surname><given-names>B</given-names></name>, <name><surname>Abbott</surname><given-names>KC</given-names></name>, <etal/>
<article-title>US Renal Data System 2018 Annual Data Report: epidemiology of
kidney disease in the United States</article-title>. <source>Am J Kidney
Dis</source>.
<year>2019</year>;<volume>73</volume>(<issue>3</issue>)(<comment>suppl
1</comment>):<fpage>A7</fpage>&#x02013;<lpage>A8</lpage>.<pub-id pub-id-type="pmid">30798791</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="book"><collab>Centers for Disease Control and
Prevention</collab>. <source>Chronic Kidney Disease in the United States,
2019</source>. <publisher-loc>Atlanta, GA</publisher-loc>:
<publisher-name>US Department of Health and Human Services, Centers for
Disease Control and Prevention</publisher-name>;
<year>2019</year>.</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Gasparini</surname><given-names>A</given-names></name>, <name><surname>Evans</surname><given-names>M</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <etal/>
<article-title>Prevalence and recognition of chronic kidney disease in Stockholm
healthcare</article-title>. <source>Nephrol Dial Transplant</source>.
<year>2016</year>;<volume>31</volume>(<issue>12</issue>):<fpage>2086</fpage>&#x02013;<lpage>2094</lpage>.
doi:<pub-id pub-id-type="doi">10.1093/ndt/gfw354</pub-id><pub-id pub-id-type="pmid">27738231</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Dharmarajan</surname><given-names>SH</given-names></name>, <name><surname>Bragg-Gresham</surname><given-names>JL</given-names></name>, <name><surname>Morgenstern</surname><given-names>H</given-names></name>, <etal/>
<article-title>State-Level Awareness of Chronic Kidney Disease in the
U.S</article-title>. <source>Am J Prev Med</source>.
<year>2017</year>;<volume>53</volume>(<issue>3</issue>):<fpage>300</fpage>&#x02013;<lpage>307</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.amepre.2017.02.015</pub-id><pub-id pub-id-type="pmid">28410862</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Hsu</surname><given-names>C-C</given-names></name>, <name><surname>Hwang</surname><given-names>S-J</given-names></name>, <name><surname>Wen</surname><given-names>C-P</given-names></name>, <etal/>
<article-title>High prevalence and low awareness of CKD in Taiwan: a study on
the relationship between serum creatinine and awareness from a nationally
representative survey</article-title>. <source>Am J Kidney Dis</source>.
<year>2006</year>;<volume>48</volume>(<issue>5</issue>):<fpage>727</fpage>&#x02013;<lpage>738</lpage>.
doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2006.07.018</pub-id><pub-id pub-id-type="pmid">17059992</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>McClellan</surname><given-names>WM</given-names></name>, <name><surname>Newsome</surname><given-names>BB</given-names></name>, <name><surname>McClure</surname><given-names>LA</given-names></name>, <etal/>
<article-title>Chronic Kidney Disease Is Often Unrecognized among Patients with
Coronary Heart Disease: The REGARDS Cohort Study</article-title>. <source>Am
J Nephrol</source>.
<year>2008</year>;<volume>29</volume>(<issue>1</issue>):<fpage>10</fpage>&#x02013;<lpage>17</lpage>.
doi:<pub-id pub-id-type="doi">10.1159/000148645</pub-id><pub-id pub-id-type="pmid">18663284</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Flessner</surname><given-names>MF</given-names></name>, <name><surname>Wyatt</surname><given-names>SB</given-names></name>, <name><surname>Akylbekova</surname><given-names>EL</given-names></name>, <etal/>
<article-title>Prevalence and Awareness of CKD Among African Americans: The
Jackson Heart Study</article-title>. <source>Am J Kidney Dis</source>.
<year>2009</year>;<volume>53</volume>(<issue>2</issue>):<fpage>238</fpage>&#x02013;<lpage>247</lpage>.
doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2008.08.035</pub-id><pub-id pub-id-type="pmid">19166799</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>McIntyre</surname><given-names>NJ</given-names></name>, <name><surname>Fluck</surname><given-names>R</given-names></name>, <name><surname>McIntyre</surname><given-names>C</given-names></name>, <name><surname>Taal</surname><given-names>M</given-names></name>. <article-title>Treatment needs and diagnosis awareness in primary care
patients with chronic kidney disease</article-title>. <source>Br J Gen
Pract</source>.
<year>2012</year>;<volume>62</volume>(<issue>597</issue>):<fpage>e227</fpage>&#x02013;<lpage>232</lpage>.
doi:<pub-id pub-id-type="doi">10.3399/bjgp12X636047</pub-id><pub-id pub-id-type="pmid">22520909</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Plantinga</surname><given-names>LC</given-names></name>, <name><surname>Boulware</surname><given-names>LE</given-names></name>, <name><surname>Coresh</surname><given-names>J</given-names></name>, <etal/>
<article-title>Patient Awareness in Chronic Kidney Disease: Trends and
Predictors</article-title>. <source>Arch Intern Med</source>.
<year>2008</year>;<volume>168</volume>(<issue>20</issue>):<fpage>2268</fpage>&#x02013;<lpage>2275</lpage>.
doi:<pub-id pub-id-type="doi">10.1001/archinte.168.20.2268</pub-id><pub-id pub-id-type="pmid">19001205</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Plantinga</surname><given-names>LC</given-names></name>, <name><surname>Tuot</surname><given-names>DS</given-names></name>, <name><surname>Powe</surname><given-names>NR</given-names></name>. <article-title>Awareness of Chronic Kidney Disease among Patients and
Providers</article-title>. <source>Adv Chronic Kidney Dis</source>.
<year>2010</year>;<volume>17</volume>(<issue>3</issue>):<fpage>225</fpage>&#x02013;<lpage>236</lpage>.
doi:<pub-id pub-id-type="doi">10.1053/j.ackd.2010.03.002</pub-id><pub-id pub-id-type="pmid">20439091</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Devraj</surname><given-names>R</given-names></name>, <name><surname>Borrego</surname><given-names>ME</given-names></name>, <name><surname>Vilay</surname><given-names>AM</given-names></name>, <name><surname>Pailden</surname><given-names>J</given-names></name>, <name><surname>Horowitz</surname><given-names>B</given-names></name>. <article-title>Awareness, self-management behaviors, health literacy
and kidney function relationships in specialty practice</article-title>.
<source>World J Nephrol</source>.
<year>2018</year>;<volume>7</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>50</lpage>.
doi:<pub-id pub-id-type="doi">10.5527/wjn.v7.i1.41</pub-id><pub-id pub-id-type="pmid">29359119</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Whaley-Connell</surname><given-names>A</given-names></name>, <name><surname>Sowers</surname><given-names>JR</given-names></name>, <name><surname>McCullough</surname><given-names>PA</given-names></name>, <etal/>
<article-title>Diabetes mellitus and CKD awareness: the Kidney Early Evaluation
Program (KEEP) and National Health and Nutrition Examination Survey
(NHANES)</article-title>. <source>Am J Kidney Dis</source>.
<year>2009</year>;<volume>53</volume>(<issue>4 Suppl
4</issue>):<fpage>S11</fpage>&#x02013;<lpage>21</lpage>.
doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2009.01.004</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Tuot</surname><given-names>DS</given-names></name>, <name><surname>Plantinga</surname><given-names>LC</given-names></name>, <name><surname>Hsu</surname><given-names>C</given-names></name>, <name><surname>Powe</surname><given-names>NR</given-names></name>. <article-title>Is Awareness of Chronic Kidney Disease Associated with
Evidence-Based Guideline-Concordant Outcomes?</article-title>
<source>Am J Nephrol</source>.
<year>2012</year>;<volume>35</volume>(<issue>2</issue>):<fpage>191</fpage>&#x02013;<lpage>197</lpage>.
doi:<pub-id pub-id-type="doi">10.1159/000335935</pub-id><pub-id pub-id-type="pmid">22286715</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Plantinga</surname><given-names>L</given-names></name>, <name><surname>Grubbs</surname><given-names>V</given-names></name>, <name><surname>Sarkar</surname><given-names>U</given-names></name>, <etal/>
<article-title>Nonsteroidal Anti-Inflammatory Drug Use Among Persons With
Chronic Kidney Disease in the United States</article-title>. <source>Ann Fam
Med</source>.
<year>2011</year>;<volume>9</volume>(<issue>5</issue>):<fpage>423</fpage>&#x02013;<lpage>430</lpage>.
doi:<pub-id pub-id-type="doi">10.1370/afm.1302</pub-id><pub-id pub-id-type="pmid">21911761</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Tuot</surname><given-names>DS</given-names></name>, <name><surname>Plantinga</surname><given-names>LC</given-names></name>, <name><surname>Judd</surname><given-names>SE</given-names></name>, <etal/>
<article-title>Healthy behaviors, risk factor control and awareness of chronic
kidney disease</article-title>. <source>Am J Nephrol</source>.
<year>2013</year>;<volume>37</volume>(<issue>2</issue>):<fpage>135</fpage>&#x02013;<lpage>143</lpage>.
doi:<pub-id pub-id-type="doi">10.1159/000346712</pub-id><pub-id pub-id-type="pmid">23392070</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Daker-White</surname><given-names>G</given-names></name>, <name><surname>Rogers</surname><given-names>A</given-names></name>, <name><surname>Kennedy</surname><given-names>A</given-names></name>, <name><surname>Blakeman</surname><given-names>T</given-names></name>, <name><surname>Blickem</surname><given-names>C</given-names></name>, <name><surname>Chew-Graham</surname><given-names>C</given-names></name>. <article-title>Non-disclosure of chronic kidney disease in primary care
and the limits of instrumental rationality in chronic illness
self-management</article-title>. <source>Soc Sci Med</source>.
<year>2015</year>;<volume>131</volume>:<fpage>31</fpage>&#x02013;<lpage>39</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.socscimed.2015.02.035</pub-id><pub-id pub-id-type="pmid">25748112</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="book"><collab>Centers for Disease Control and
Prevention (CDC)</collab>. <chapter-title>National Center for Health
Statistics (NCHS</chapter-title>). <source>National Health and Nutrition
Examination Survey Data</source>. <publisher-loc>Hyattsville,
MD</publisher-loc>: <publisher-name>U.S. Department of Health and Human
Services, Centers for Disease Control and Prevention</publisher-name>;
<year>1999</year>
<comment><ext-link ext-link-type="uri" xlink:href="https://wwwn.cdc.gov/nchs/nhanes/">https://wwwn.cdc.gov/nchs/nhanes/</ext-link>.</comment>
<comment>Accessed</comment>
<date-in-citation>May 7, 2019</date-in-citation>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Levey</surname><given-names>AS</given-names></name>, <name><surname>Stevens</surname><given-names>LA</given-names></name>, <name><surname>Schmid</surname><given-names>CH</given-names></name>, <etal/>
<article-title>A New Equation to Estimate Glomerular Filtration
Rate</article-title>. <source>Ann Intern Med</source>.
<year>2009</year>;<volume>150</volume>(<issue>9</issue>):<fpage>604</fpage>&#x02013;<lpage>612</lpage>.<pub-id pub-id-type="pmid">19414839</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Tangri</surname><given-names>N</given-names></name>, <name><surname>Stevens</surname><given-names>LA</given-names></name>, <name><surname>Griffith</surname><given-names>J</given-names></name>, <etal/>
<article-title>A Predictive Model for Progression of Chronic Kidney Disease to
Kidney Failure</article-title>. <source>JAMA</source>.
<year>2011</year>;<volume>305</volume>(<issue>15</issue>):<fpage>1553</fpage>&#x02013;<lpage>1559</lpage>.
doi:<pub-id pub-id-type="doi">10.1001/jama.2011.451</pub-id><pub-id pub-id-type="pmid">21482743</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Tangri</surname><given-names>N</given-names></name>, <name><surname>Grams</surname><given-names>ME</given-names></name>, <name><surname>Levey</surname><given-names>AS</given-names></name>, <etal/>
<article-title>Multinational assessment of accuracy of equations for predicting
risk of kidney failure: a meta-analysis</article-title>.
<source>JAMA</source>.
<year>2016</year>;<volume>315</volume>(<issue>2</issue>):<fpage>164</fpage>&#x02013;<lpage>174</lpage>.
doi:<pub-id pub-id-type="doi">10.1001/jama.2015.18202</pub-id><pub-id pub-id-type="pmid">26757465</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Peeters</surname><given-names>MJ</given-names></name>, <name><surname>van Zuilen</surname><given-names>AD</given-names></name>, <name><surname>van den Brand</surname><given-names>JAJG</given-names></name>, <etal/>
<article-title>Validation of the kidney failure risk equation in European CKD
patients</article-title>. <source>Nephrol Dial Transplant</source>.
<year>2013</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1773</fpage>&#x02013;<lpage>1779</lpage>.
doi:<pub-id pub-id-type="doi">10.1093/ndt/gft063</pub-id><pub-id pub-id-type="pmid">23645476</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Hingwala</surname><given-names>J</given-names></name>, <name><surname>Wojciechowski</surname><given-names>P</given-names></name>, <name><surname>Hiebert</surname><given-names>B</given-names></name>, <etal/>
<article-title>Risk-Based Triage for Nephrology Referrals Using the Kidney
Failure Risk Equation</article-title>. <source>Can J Kidney Health
Dis</source>. <year>2017</year>;<volume>4</volume>. doi:<pub-id pub-id-type="doi">10.1177/2054358117722782</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Tangri</surname><given-names>N</given-names></name>, <name><surname>Ferguson</surname><given-names>T</given-names></name>, <name><surname>Komenda</surname><given-names>P</given-names></name>. <article-title>Pro: Risk scores for chronic kidney disease progression
are robust, powerful and ready for implementation</article-title>.
<source>Nephrology Dialysis Transplantation</source>.
<year>2017</year>;<volume>32</volume>(<issue>5</issue>):<fpage>748</fpage>&#x02013;<lpage>751</lpage>.
doi:<pub-id pub-id-type="doi">10.1093/ndt/gfx067</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Crim</surname><given-names>MT</given-names></name>, <name><surname>Yoon</surname><given-names>SS</given-names></name>, <name><surname>Ortiz</surname><given-names>E</given-names></name>, <etal/>
<article-title>National Surveillance Definitions for Hypertension Prevalence and
Control Among Adults</article-title>. <source>Circ Cardiovasc Qual
Outcomes</source>.
<year>2012</year>;<volume>5</volume>(<issue>3</issue>):<fpage>343</fpage>&#x02013;<lpage>351</lpage>.
doi:<pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.111.963439</pub-id><pub-id pub-id-type="pmid">22550130</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><collab>International Expert Committee
Report on the Role of the A1C Assay in the Diagnosis of Diabetes</collab>.
<source>Diabetes Care</source>.
<year>2009</year>;<volume>32</volume>(<issue>7</issue>):<fpage>1327</fpage>&#x02013;<lpage>1334</lpage>.
doi:<pub-id pub-id-type="doi">10.2337/dc09-9033</pub-id><pub-id pub-id-type="pmid">19502545</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="book"><name><surname>Vittinghoff</surname><given-names>E</given-names></name>, <name><surname>Glidden</surname><given-names>DV</given-names></name>, <name><surname>Shiboski</surname><given-names>SC</given-names></name>, <name><surname>McCulloch</surname><given-names>CE</given-names></name>. <source>Regression Methods in Biostatistics</source>.
<publisher-loc>New York</publisher-loc>:
<publisher-name>Springer</publisher-name>;
<year>2005</year>.</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Delanaye</surname><given-names>P</given-names></name>, <name><surname>Jager</surname><given-names>KJ</given-names></name>, <name><surname>B&#x000f6;kenkamp</surname><given-names>A</given-names></name>, <etal/>
<article-title>CKD: A Call for an Age-Adapted Definition</article-title>.
<source>JASN</source>.
<year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1785</fpage>&#x02013;<lpage>1805</lpage>.
doi:<pub-id pub-id-type="doi">10.1681/ASN.2019030238</pub-id><pub-id pub-id-type="pmid">31506289</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Wesson</surname><given-names>DE</given-names></name>. <article-title>Does eGFR by Any Number Mean the Same?</article-title>
<source>JASN</source>.
<year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1806</fpage>&#x02013;<lpage>1807</lpage>.
doi:<pub-id pub-id-type="doi">10.1681/ASN.2019070749</pub-id><pub-id pub-id-type="pmid">31506291</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Chertow</surname><given-names>GM</given-names></name>, <name><surname>Beddhu</surname><given-names>S</given-names></name>. <article-title>Modification of eGFR-Based CKD Definitions: Perfect, or
Enemy of the Good?</article-title>
<source>JASN</source>.
<year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1807</fpage>&#x02013;<lpage>1809</lpage>.
doi:<pub-id pub-id-type="doi">10.1681/ASN.2019070743</pub-id><pub-id pub-id-type="pmid">31506290</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Parker</surname><given-names>JD</given-names></name>, <name><surname>Talih</surname><given-names>M</given-names></name>, <name><surname>Malec</surname><given-names>DJ</given-names></name>, <etal/>
<article-title>National Center for Health Statistics Data Presentation Standards
for Proportions</article-title>. <source>Vital Health Stat 2</source>.
<year>2017</year>;(<issue>175</issue>):<fpage>1</fpage>&#x02013;<lpage>22</lpage>.</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Greer</surname><given-names>RC</given-names></name>, <name><surname>Cooper</surname><given-names>LA</given-names></name>, <name><surname>Crews</surname><given-names>DC</given-names></name>, <name><surname>Powe</surname><given-names>NR</given-names></name>, <name><surname>Boulware</surname><given-names>LE</given-names></name>. <article-title>Quality of Patient-Physician Discussions About CKD in
Primary Care: A Cross-sectional Study</article-title>. <source>Am J Kidney
Dis</source>.
<year>2011</year>;<volume>57</volume>(<issue>4</issue>):<fpage>583</fpage>&#x02013;<lpage>591</lpage>.
doi:<pub-id pub-id-type="doi">10.1053/j.ajkd.2010.08.027</pub-id><pub-id pub-id-type="pmid">21131116</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Greer</surname><given-names>RC</given-names></name>, <name><surname>Crews</surname><given-names>DC</given-names></name>, <name><surname>Boulware</surname><given-names>LE</given-names></name>. <article-title>Challenges Perceived by Primary Care Providers to
Educating Patients About Chronic Kidney Disease</article-title>. <source>J
Ren Care</source>.
<year>2012</year>;<volume>38</volume>(<issue>4</issue>):<fpage>174</fpage>&#x02013;<lpage>181</lpage>.
doi:<pub-id pub-id-type="doi">10.1111/j.1755-6686.2012.00323.x</pub-id><pub-id pub-id-type="pmid">23176576</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Crinson</surname><given-names>I</given-names></name>, <name><surname>Gallagher</surname><given-names>H</given-names></name>, <name><surname>Thomas</surname><given-names>N</given-names></name>, <name><surname>de Lusignan</surname><given-names>S</given-names></name>. <article-title>How ready is general practice to improve quality in
chronic kidney disease? A diagnostic analysis</article-title>. <source>Br J
Gen Pract</source>.
<year>2010</year>;<volume>60</volume>(<issue>575</issue>):<fpage>403</fpage>&#x02013;<lpage>409</lpage>.
doi:<pub-id pub-id-type="doi">10.3399/bjgp10X502100</pub-id><pub-id pub-id-type="pmid">20529495</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Smekal</surname><given-names>MD</given-names></name>, <name><surname>Tam-Tham</surname><given-names>H</given-names></name>, <name><surname>Finlay</surname><given-names>J</given-names></name>, <etal/>
<article-title>Perceived Benefits and Challenges of a Risk-Based Approach to
Multidisciplinary Chronic Kidney Disease Care: A Qualitative Descriptive
Study</article-title>. <source>Can J Kidney Health Dis</source>.
<year>2018</year>;<volume>5</volume>. doi:<pub-id pub-id-type="doi">10.1177/2054358118763809</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Smekal</surname><given-names>MD</given-names></name>, <name><surname>Tam-Tham</surname><given-names>H</given-names></name>, <name><surname>Finlay</surname><given-names>J</given-names></name>, <etal/>
<article-title>Patient and provider experience and perspectives of a risk-based
approach to multidisciplinary chronic kidney disease care: a mixed methods
study</article-title>. <source>BMC Nephrol</source>.
<year>2019</year>;<volume>20</volume>. doi:<pub-id pub-id-type="doi">10.1186/s12882-019-1269-2</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Blakeman</surname><given-names>T</given-names></name>, <name><surname>Protheroe</surname><given-names>J</given-names></name>, <name><surname>Chew-Graham</surname><given-names>C</given-names></name>, <name><surname>Rogers</surname><given-names>A</given-names></name>, <name><surname>Kennedy</surname><given-names>A</given-names></name>. <article-title>Understanding the management of early-stage chronic
kidney disease in primary care: a qualitative study</article-title>.
<source>Br J Gen Pract</source>.
<year>2012</year>;<volume>62</volume>(<issue>597</issue>):<fpage>e233</fpage>&#x02013;<lpage>242</lpage>.
doi:<pub-id pub-id-type="doi">10.3399/bjgp12X636056</pub-id><pub-id pub-id-type="pmid">22520910</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Abdi</surname><given-names>Z</given-names></name>, <name><surname>Gallagher</surname><given-names>H</given-names></name>, <name><surname>O&#x02019;Donoghue</surname><given-names>D</given-names></name>. <article-title>Telling the truth: why disclosure matters in chronic
kidney disease</article-title>. <source>Br J Gen Pract</source>.
<year>2012</year>;<volume>62</volume>(<issue>597</issue>):<fpage>172</fpage>&#x02013;<lpage>173</lpage>.
doi:<pub-id pub-id-type="doi">10.3399/bjgp12X635958</pub-id><pub-id pub-id-type="pmid">22520891</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Tuot</surname><given-names>DS</given-names></name>, <name><surname>Zhu</surname><given-names>Y</given-names></name>, <name><surname>Velasquez</surname><given-names>A</given-names></name>, <etal/>
<article-title>Variation in Patients&#x02019; Awareness of CKD according to How
They Are Asked</article-title>. <source>Clin J Am Soc Nephrol</source>.
<year>2016</year>;<volume>11</volume>(<issue>9</issue>):<fpage>1566</fpage>&#x02013;<lpage>1573</lpage>.
doi:<pub-id pub-id-type="doi">10.2215/CJN.00490116</pub-id><pub-id pub-id-type="pmid">27340288</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Tuot</surname><given-names>DS</given-names></name>, <name><surname>Wong</surname><given-names>KK</given-names></name>, <name><surname>Velasquez</surname><given-names>A</given-names></name>, <etal/>
<article-title>CKD Awareness in the General Population: Performance of
CKD-Specific Questions</article-title>. <source>Kidney Medicine</source>.
<year>2019</year>;<volume>1</volume>(<issue>2</issue>):<fpage>43</fpage>&#x02013;<lpage>50</lpage>.
doi:<pub-id pub-id-type="doi">10.1016/j.xkme.2019.01.005</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><collab>National Kidney
Foundation</collab>. <article-title>K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and
stratification</article-title>. <source>Am J Kidney Dis</source>.
<year>2002</year>;<volume>39</volume>(<issue>2 Suppl
1</issue>):<fpage>S1</fpage>&#x02013;<lpage>266</lpage>.<pub-id pub-id-type="pmid">11904577</pub-id></mixed-citation></ref><ref id="R41"><label>30a.</label><mixed-citation publication-type="web"><collab>National Kidney Foundation</collab>.
<source>Public Awareness Initiative for AAKH Announced as a Public-Private
Partnership with NKF and ASN</source>. <month>11</month>
<day>4</day>, <year>2019</year>
<comment><ext-link ext-link-type="uri" xlink:href="https://www.kidney.org/news/aakh-announced-public-private-partnership-nkf-asn">https://www.kidney.org/news/aakh-announced-public-private-partnership-nkf-asn</ext-link>
Accessed</comment>
<date-in-citation>Jan 6 2020</date-in-citation></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1:</label><caption><title>CKD awareness by 5-year Kidney Failure Risk, NHANES 1999&#x02013;2016.</title><p id="P51">P values reported are for linear trends. ESKD risk is the estimated
5-year risk of dialysis or kidney transplant, calculated using the 4-variable
Kidney Failure Risk Equation. In panel B, estimates are standardized to the
1999&#x02013;2004 age distribution. In panel C, adjustment is for sex,
race/ethnicity, presence of diabetes, and presence of hypertension. CKD =
chronic kidney disease; NHANES = National Health and Nutrition Examination
Survey; ESKD = end-stage kidney disease.</p></caption><graphic xlink:href="nihms-1568543-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2:</label><caption><title>CKD Awareness by Age and Kidney Failure Risk</title><p id="P52">ESKD risk is the estimated 5-year risk of dialysis or kidney transplant,
calculated using the 4-variable Kidney Failure Risk Equation. In panel B,
adjustment is for sex, race/ethnicity, presence of hypertension, and presence of
diabetes. P values reported are for tests for interaction. CKD = chronic kidney
disease.</p></caption><graphic xlink:href="nihms-1568543-f0002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3:</label><caption><title>Comparative Awareness of CKD, Hypertension, and Diabetes, NHANES
1999&#x02013;2016</title><p id="P53">P values reported are for linear trends. Diabetes awareness was defined
as self-reported diabetes, insulin use, or diabetic pill use among persons with
glycohemoglobin A1c &#x02265; 6.5% or documented diabetes medication use.
Hypertension awareness was defined as self-reported hypertension or high blood
pressure medication use among persons with systolic blood pressure &#x02265;140
mmHg, diastolic blood pressure &#x02265;90 mmHg, or documented antihypertensive
medication use. CKD awareness was defined as reporting having been told by a
health provider one had &#x0201c;weak or failing kidneys&#x0201d;, among persons
with estimated glomerular filtration rate 15 to &#x0003c;60
ml/min/1.73m<sup>2</sup> (defining CKD stages 3&#x02013;4) or &#x02265;15%
5-year risk of dialysis or kidney transplant, calculated using the 4-variable
Kidney Failure Risk Equation (defining CKD with &#x02265;15% ESKD risk)
respectively. In panel B, adjustment is for age, sex, race/ethnicity, presence
of diabetes, and presence of hypertension. CKD = chronic kidney disease, ESKD =
end-stage kidney disease.</p></caption><graphic xlink:href="nihms-1568543-f0003"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1:</label><caption><p id="P54">Characteristics of U.S. adults with CKD by estimated 5-year kidney
failure risk, NHANES 1999&#x02013;2016.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Characteristic</th><th colspan="4" align="left" valign="top" rowspan="1">estimated 5-year kidney failure
risk</th><th align="left" valign="top" rowspan="1" colspan="1">P</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;2%</th><th align="left" valign="top" rowspan="1" colspan="1">2%&#x0003c;5%</th><th align="left" valign="top" rowspan="1" colspan="1">5%&#x02013;&#x0003c;15%</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;15%</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">No. of participants</td><td align="left" valign="top" rowspan="1" colspan="1">2,818</td><td align="left" valign="top" rowspan="1" colspan="1">423</td><td align="left" valign="top" rowspan="1" colspan="1">258</td><td align="left" valign="top" rowspan="1" colspan="1">214</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean Age</td><td align="left" valign="top" rowspan="1" colspan="1">71 (71, 72)</td><td align="left" valign="top" rowspan="1" colspan="1">73 (71, 74)</td><td align="left" valign="top" rowspan="1" colspan="1">71 (69, 73)</td><td align="left" valign="top" rowspan="1" colspan="1">67 (64, 69)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Women</td><td align="left" valign="top" rowspan="1" colspan="1">60.4 (58.3, 62.5)</td><td align="left" valign="top" rowspan="1" colspan="1">58.6 (53.1, 64.2)</td><td align="left" valign="top" rowspan="1" colspan="1">50.5 (44.0, 57.0)</td><td align="left" valign="top" rowspan="1" colspan="1">46.7 (38.1, 55.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Race/ethnicity</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Non-Hispanic white</td><td align="left" valign="top" rowspan="1" colspan="1">84.0 (81.9, 86.0)</td><td align="left" valign="top" rowspan="1" colspan="1">74.9 (70.2, 79.6)</td><td align="left" valign="top" rowspan="1" colspan="1">71.9 (65.5, 78.2)</td><td align="left" valign="top" rowspan="1" colspan="1">57.8 (48.8, 66.8)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Non-Hispanic black</td><td align="left" valign="top" rowspan="1" colspan="1">7.6 (6.4, 8.8)</td><td align="left" valign="top" rowspan="1" colspan="1">12.1 (9.1, 15.1)</td><td align="left" valign="top" rowspan="1" colspan="1">13.3 (9.2, 17.5)</td><td align="left" valign="top" rowspan="1" colspan="1">20.4 (14.5, 26.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mexican-American</td><td align="left" valign="top" rowspan="1" colspan="1">2.0 (1.4, 2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3.9 (2.4, 5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">4.9 (2.1, 7.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8.9 (4.9, 12.8)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other Hispanic</td><td align="left" valign="top" rowspan="1" colspan="1">3.0 (1.8, 4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">2.6 (1.0, 4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">3.7 (1.6, 5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">3.9 (1.2, 6.6)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Other</td><td align="left" valign="top" rowspan="1" colspan="1">3.5 (2.6, 4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (3.0, 10.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6.2 (2.4, 10.1)</td><td align="left" valign="top" rowspan="1" colspan="1">9.0 (2.2, 15.8)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Health insurance, any</td><td align="left" valign="top" rowspan="1" colspan="1">96.3 (95.3, 97.2)</td><td align="left" valign="top" rowspan="1" colspan="1">95.5 (92.5, 98.5)</td><td align="left" valign="top" rowspan="1" colspan="1">95.3 (92.6, 98.0)</td><td align="left" valign="top" rowspan="1" colspan="1">95.0 (90.9, 99.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Private insurance</td><td align="left" valign="top" rowspan="1" colspan="1">61.2 (58.3, 64.2)</td><td align="left" valign="top" rowspan="1" colspan="1">58.0 (51.7, 64.5)</td><td align="left" valign="top" rowspan="1" colspan="1">49.0 (41.2, 56.9)</td><td align="left" valign="top" rowspan="1" colspan="1">48.9 (40.4, 57.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicare</td><td align="left" valign="top" rowspan="1" colspan="1">70.9 (68.3, 73.6)</td><td align="left" valign="top" rowspan="1" colspan="1">75.6 (69.9, 81.4)</td><td align="left" valign="top" rowspan="1" colspan="1">72.9 (65.5, 80.4)</td><td align="left" valign="top" rowspan="1" colspan="1">68.2 (59.9, 76.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Medicaid</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (5.4, 7.8)</td><td align="left" valign="top" rowspan="1" colspan="1">11.7 (7.9, 15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">12.5 (6.9, 18.0)</td><td align="left" valign="top" rowspan="1" colspan="1">14.4 (8.6, 20.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Reported a routine site of care</td><td align="left" valign="top" rowspan="1" colspan="1">96.8 (96.0, 97.6)</td><td align="left" valign="top" rowspan="1" colspan="1">96.0 (93.6, 98.5)</td><td align="left" valign="top" rowspan="1" colspan="1">97.9 (96.2, 99.7)</td><td align="left" valign="top" rowspan="1" colspan="1">98.6 (97.0, 100.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High school education or above</td><td align="left" valign="top" rowspan="1" colspan="1">75.3 (73.0, 77.7)</td><td align="left" valign="top" rowspan="1" colspan="1">67.0 (61.3, 72.7)</td><td align="left" valign="top" rowspan="1" colspan="1">63.4 (57.5, 70.4)</td><td align="left" valign="top" rowspan="1" colspan="1">66.0 (58.6, 73.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Current smoker</td><td align="left" valign="top" rowspan="1" colspan="1">18.7 (15.8, 21.6)</td><td align="left" valign="top" rowspan="1" colspan="1">22.6 (15.8, 29.4)</td><td align="left" valign="top" rowspan="1" colspan="1">20.3 (11.4, 29.2)</td><td align="left" valign="top" rowspan="1" colspan="1">26.4 (16.2, 36.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Obesity</td><td align="left" valign="top" rowspan="1" colspan="1">36.2 (34.3, 38.1)</td><td align="left" valign="top" rowspan="1" colspan="1">41.7 (34.4, 49.1)</td><td align="left" valign="top" rowspan="1" colspan="1">49.5 (41.3, 57.8)</td><td align="left" valign="top" rowspan="1" colspan="1">52.0 (43.1, 61.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Family history of diabetes</td><td align="left" valign="top" rowspan="1" colspan="1">39.6 (37.2, 41.9)</td><td align="left" valign="top" rowspan="1" colspan="1">43.6 (37.6, 49.7)</td><td align="left" valign="top" rowspan="1" colspan="1">43.3 (35.5, 51.0)</td><td align="left" valign="top" rowspan="1" colspan="1">61.9 (53.6, 70.2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes</td><td align="left" valign="top" rowspan="1" colspan="1">22.6 (20.7, 24.5)</td><td align="left" valign="top" rowspan="1" colspan="1">37.8 (31.6, 44.1)</td><td align="left" valign="top" rowspan="1" colspan="1">46.4 (39.5, 53.3)</td><td align="left" valign="top" rowspan="1" colspan="1">55.6 (46.2, 65.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="left" valign="top" rowspan="1" colspan="1">80.3 (77.9, 82.6)</td><td align="left" valign="top" rowspan="1" colspan="1">92.4 (88.6, 96.2)</td><td align="left" valign="top" rowspan="1" colspan="1">94.8 (91.9, 97.8)</td><td align="left" valign="top" rowspan="1" colspan="1">92.9 (87.9, 98.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Coronary artery disease</td><td align="left" valign="top" rowspan="1" colspan="1">12.5 (10.9, 14.0)</td><td align="left" valign="top" rowspan="1" colspan="1">18.7 (14.0, 23.5)</td><td align="left" valign="top" rowspan="1" colspan="1">22.3 (16.0, 28.6)</td><td align="left" valign="top" rowspan="1" colspan="1">27.6 (19.5, 35.7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" valign="top" rowspan="1" colspan="1">10.6 (9.1, 12.1)</td><td align="left" valign="top" rowspan="1" colspan="1">17.1 (13.0, 21.2)</td><td align="left" valign="top" rowspan="1" colspan="1">24.2 (18.2, 30.2)</td><td align="left" valign="top" rowspan="1" colspan="1">27.8 (19.9, 35.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CKD GFR category</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;G3a</td><td align="left" valign="top" rowspan="1" colspan="1">84.8 (83.4, 86.3)</td><td align="left" valign="top" rowspan="1" colspan="1">19.5 (15.1, 24.0)</td><td align="left" valign="top" rowspan="1" colspan="1">7.4 (3.5, 11.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;G3b</td><td align="left" valign="top" rowspan="1" colspan="1">15.2 (13.7, 16.6)</td><td align="left" valign="top" rowspan="1" colspan="1">69.0 (63.1, 74.9)</td><td align="left" valign="top" rowspan="1" colspan="1">54.6 (47.3, 61.8)</td><td align="left" valign="top" rowspan="1" colspan="1">34.2 (25.7, 42.7)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;G4</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">11.5 (7.3, 15.7)</td><td align="left" valign="top" rowspan="1" colspan="1">38.1 (31.1, 45.1)</td><td align="left" valign="top" rowspan="1" colspan="1">65.8 (57.3, 74.3)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR (ml/min/1.73m<sup>2</sup>)<xref rid="TFN2" ref-type="table-fn">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">52 (6)</td><td align="left" valign="top" rowspan="1" colspan="1">39 (8)</td><td align="left" valign="top" rowspan="1" colspan="1">33 (8)</td><td align="left" valign="top" rowspan="1" colspan="1">26 (8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UACR (mg/g)<xref rid="TFN3" ref-type="table-fn">**</xref></td><td align="left" valign="top" rowspan="1" colspan="1">9 (5, 22)</td><td align="left" valign="top" rowspan="1" colspan="1">41 (13, 135)</td><td align="left" valign="top" rowspan="1" colspan="1">63 (34, 330)</td><td align="left" valign="top" rowspan="1" colspan="1">934 (322, 2763)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P55">Values in parentheses are 95% confidence intervals.</p></fn><fn id="TFN2"><label>*</label><p id="P56">Mean +/&#x02212; standard deviation</p></fn><fn id="TFN3"><label>**</label><p id="P57">median [interquartile range]</p></fn><fn id="TFN4"><p id="P58">Reported figures are adjusted for complex survey design used by
NHANES to estimate nationally representative results.</p></fn><fn id="TFN5"><p id="P59">Obesity defined as body mass index &#x02265;30 kg/m<sup>2</sup>.</p></fn><fn id="TFN6"><p id="P60">CKD = chronic kidney disease; NHANES = National Health and Nutrition
Examination Survey; SD = standard deviation; eGFR = estimated glomerular
filtration rate, calculated by Chronic Kidney Disease-Epidemiology
Collaboration (CKD-EPI) equation; UACR = urinary albumin-creatinine
ratio</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2:</label><caption><p id="P61">Association of Kidney Failure Risk and CKD Awareness by Multivariable
Logistic Regression among U.S. Adults with CKD G3-G4 Based on NHANES
1999&#x02013;2016.</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="left" valign="top" colspan="1">Kidney Failure Risk Group</th><th rowspan="2" align="left" valign="top" colspan="1">Unadjusted OR (95% CI)</th><th colspan="2" align="left" valign="top" rowspan="1">Adjusted OR (95% CI)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Model 1<xref rid="TFN7" ref-type="table-fn">*</xref></th><th align="left" valign="top" rowspan="1" colspan="1">Model 2<xref rid="TFN8" ref-type="table-fn">**</xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;2%</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td><td align="left" valign="top" rowspan="1" colspan="1">1.00 (reference)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2%&#x02013;&#x0003c;5%</td><td align="left" valign="top" rowspan="1" colspan="1">3.02 (2.11&#x02013;4.33)</td><td align="left" valign="top" rowspan="1" colspan="1">3.14 (2.22&#x02013;4.43)</td><td align="left" valign="top" rowspan="1" colspan="1">2.76 (1.90&#x02013;4.01)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5%&#x02013;&#x0003c;15%</td><td align="left" valign="top" rowspan="1" colspan="1">10.10 (7.11&#x02013;14.34)</td><td align="left" valign="top" rowspan="1" colspan="1">10.19 (7.04&#x02013;14.74)</td><td align="left" valign="top" rowspan="1" colspan="1">9.36 (6.30&#x02013;13.90)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02265;15%</td><td align="left" valign="top" rowspan="1" colspan="1">12.96 (8.76&#x02013;19.16)</td><td align="left" valign="top" rowspan="1" colspan="1">11.20 (7.42&#x02013;16.92)</td><td align="left" valign="top" rowspan="1" colspan="1">9.24 (5.97&#x02013;14.31)</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><label>*</label><p id="P62">Adjusted for age, sex, and race/ethnicity.</p></fn><fn id="TFN8"><label>**</label><p id="P63">Adjusted for age, sex, race/ethnicity, hypertension status, and
diabetes status.</p></fn><fn id="TFN9"><p id="P64">Kidney failure risk was 5-year risk, determined using the 4-variable
Kidney Failure Risk Equation.</p></fn><fn id="TFN10"><p id="P65">CKD = chronic kidney disease; NHANES = National Health and Nutrition
Examination Survey; OR = odds ratio; CI = confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>